Browse News

Found 3,300 articles

• ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting

  3/24/2023

  ProfoundBio will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-directed exatecan-based antibody-drug conjugate (ADC) with a novel hydrophilic linker, at the American Association for Cancer Research (AACR) Annual Meeting being held April 14 – 19, 2023.

• Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

  3/23/2023

  Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.

• Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments

  3/23/2023

  Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today reported financial results for the fourth quarter ended December 31, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones.

• BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

  3/23/2023

  BioAtla, Inc. (Nasdaq: BCAB) today announced its financial results for the fourth quarter and full year ended December 31, 2022, and provided highlights on its clinical programs. 

• Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

  3/22/2023

  Biohaven Ltd. (NYSE: BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders.

• CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

  3/22/2023

  CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.

• 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

  3/22/2023

  Chinese leading biopharmaceutical company 3SBio announced its 2022 annual results.

• Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

  3/22/2023

  Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported financial results for the full year ended December 31, 2022, and provided a corporate update.

• Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

  3/21/2023

  Lantern Pharma Inc. announced that Lantern management and employees will be presenting at three upcoming events: Rare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET.

• Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

  3/20/2023

  Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction and pancreatic adenocarcinomas.

• Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials

  3/20/2023

  New data from Daiichi Sankyo’s patritumab deruxtecan from two early trials in patients with previously treated EGFR-mutated metastatic non-small cell lung cancer or HER3 expressing metastatic breast cancer were presented during two Presidential Sessions at the Japanese Society of Medical Oncology Annual Meeting.

• Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

  3/20/2023

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.

• Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million

  3/17/2023

  Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

• Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

  3/16/2023

  Pyxis Oncology, Inc. today announced dosing of the first subject in a Phase 1 trial of PYX-201. PYX-201 is a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen, that is an integral component of the extracellular matrix in tumors.

• ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

  3/15/2023

  ADC Therapeutics SA announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission.

• ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease

  3/15/2023

  ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”) today announces it is working on the development of its lead candidate, the AD04™ compound for the treatment of early Alzheimer’s disease (AD).

• Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

  3/15/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced two upcoming poster presentations at the American Association for Cancer Research Meeting 2023 in Orlando, Florida.

• Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

  3/15/2023

  Lantern Pharma Inc. today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details on the AACR presentation are provided below.

• MacroGenics Provides Corporate Update and 2022 Financial Results

  3/15/2023

  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2022.

• ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

  3/14/2023

  ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.